$1.00
0.99% today
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US69353Y1038
Symbol
PMVP

PMV Pharmaceuticals Inc Stock price

$1.00
-0.32 24.24% 1M
-0.49 32.89% 6M
-0.51 33.77% YTD
-0.79 44.13% 1Y
-21.43 95.54% 3Y
-17.00 94.44% 5Y
-17.00 94.44% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
-0.01 0.99%
ISIN
US69353Y1038
Symbol
PMVP
Sector
Industry

Key metrics

Market capitalization $52.45m
Enterprise Value $-115.81m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.23
P/B ratio (TTM) P/B ratio 0.30
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-85.45m
Free Cash Flow (TTM) Free Cash Flow $-51.94m
Cash position $169.45m
EPS (TTM) EPS $-1.14
P/E forward negative
Short interest 2.00%
Show more

Is PMV Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

PMV Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a PMV Pharmaceuticals Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a PMV Pharmaceuticals Inc forecast:

Buy
100%

Financial data from PMV Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 1.14 1.14
3% 3%
-
-1.14 -1.14
3% 3%
-
- Selling and Administrative Expenses 26 26
11% 11%
-
- Research and Development Expense 57 57
5% 5%
-
-84 -84
7% 7%
-
- Depreciation and Amortization 1.14 1.14
3% 3%
-
EBIT (Operating Income) EBIT -85 -85
7% 7%
-
Net Profit -59 -59
15% 15%
-

In millions USD.

Don't miss a Thing! We will send you all news about PMV Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PMV Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors; more than 90% of sites activated across the U.S., Europe, U.K., and Asia-Pacific; interim analysis data expected mid-2025 Enrollment commenced in the MD Anderson Cancer Center investigator-initiated Phase 1b study ev...
Neutral
GlobeNewsWire
about 2 months ago
PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following in...

Company Profile

PMV Pharmaceuticals, Inc. engages in the development of p53 targeted small molecule drugs for the treatment of cancer. It combines unique biological understanding with pharmaceutical development focus. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in 2013 and is headquartered in New Jersey, NY.

Head office United States
CEO David Mack
Employees 47
Founded 2013
Website www.pmvpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today